Novel chiral ferrocenylpyrazolo[1,5-a][1,4]diazepin-4-one derivatives-Synthesis, characterization and inhibition against lung cancer cells

European Journal of Medicinal Chemistry

Volumn 63, Issue , 2013, Pages 256-268

  Shen, Shi Li ^a   Shao, Jin Hui ^a   Luo, Ji Zhuang ^a   Liu, Jin Ting ^a   Miao, Jun Ying ^a   Zhao, Bao Xiang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle arrest; Chiral diazepinone; Ferrocene; Lung cancer cells; Pyrazole

Indexed keywords

2 FERROCENYL 5 (2 FLUOROPHENETHYL) 7 HYDROXY 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 4 ONE; 2 FERROCENYL 5 (4 FLUOROPHENETHYL) 7 HYDROXY 5,6,7,8 TETRAHDYRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 4 ONE; 2 FERROCENYL 7 HYDROXY 5 (3 METHOXYPHENETHYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 4 ONE; 2 FERROCENYL 7 HYDROXY 5 PHENETHYL 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 4 ONE; 5 (2 FLUOROPHENETHYL) 7 HYDROXY 2 FERROCENYL 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 4 ONE; 5 ARYLETHYL 2 FERROCENYL 7 HYDROXY 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 4 ONE; 7 HYDROXY 5 (3 METHOXYPHENETHYL) 2 PHENYL 5,6,7,8 TETRAHYDROPROPYRAZOLO[1,5 A][1,4]DIAZEPIN 4 ONE; ANTINEOPLASTIC AGENT; BENZENE; DIAZEPINE DERIVATIVE; DIETHYL 1,1' [(PHENETHYLAZANEDIYL)BIS(2 HDYROXYPROPANE 3,1 DIYL)]BIS(3 FERROCENYL 1H PYRAZOLE 5 CARBOXYLATE); UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL GROWTH; CELL LINE; CHIRALITY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LUNG CANCER; MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE; X RAY ANALYSIS;

APOPTOSIS; AZEPINES; AZIRINES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROCHEMICAL TECHNIQUES; FERROUS COMPOUNDS; FLOW CYTOMETRY; HUMANS; HYDROGEN BONDING; LUNG NEOPLASMS; MICROSCOPY, FLUORESCENCE; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PYRAZOLES; STEREOISOMERISM;

EID: 84874941515     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.02.016     Document Type: Article

References (65)

1. M. Bartucci, S. Svensson, P. Romania, R. Dattilo, M. Patrizii, M. Signore, S. Navarra, F. Lotti, M. Biffoni, E. Pilozzi, E. Duranti, S. Martinelli, C. Rinaldo, A. Zeuner, M. Maugeri-Saccà, A. Eramo, and R.D. Maria Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy Cell. Death Differ. 19 2012 768 778
2. L.G. Collins, C. Haines, R. Perkel, and R.E. Enck Lung cancer: diagnosis and management Am. Fam. Physician 75 2007 56 63
3. G.M. Nitulescu, C. Draghici, and A.V. Missir Synthesis of new pyrazole derivatives and their anticancer evaluation Eur. J. Med. Chem. 45 2010 4914 4919
4. S. Bondock, W. Fadaly, and M.A. Metwally Synthesis and antimicrobial activity of some new thiazole, thiophene and pyrazole derivatives containing benzothiazole moiety Eur. J. Med. Chem. 45 2010 3692 3701
5. O. Rosati, M. Curini, M.C. Marcotullio, A. Macchiarulo, M. Perfumi, L. Mattioli, F. Rismondob, and G. Cravotto Synthesis, docking studies and anti-inflammatory activity of 4,5,6,7-tetrahydro-2H-indazole derivatives Bioorg. Med. Chem. 15 2007 3463 3473
6. M.S. Christodoulou, S. Liekens, K.M. Kasiotis, and S.A. Haroutounian Novel pyrazole derivatives: synthesis and evaluation of anti-angiogenic activity Bioorg. Med. Chem. 18 2010 4338 4350
7. D.M. Bailey, P.E. Hansen, A.G. Hlavac, E.R. Baizman, J. Pear, A.F. DeFelice, and M.E. Feigensonf 3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants J. Med. Chem. 28 1985 256 260
8. B.P. Bandgar, S.S. Gawande, R.G. Bodade, N.M. Gawande, and C.N. Khobragade Synthesis and biological evaluation of a novel series of pyrazole chalcones as anti-inflammatory, antioxidant and antimicrobial agents Bioorg. Med. Chem. 17 2009 8168 8173
9. S.R. Shih, T.Y. Chu, G.R. Reddy, S.N. Tseng, H.L. Chen, W.F. Tang, M.S. Wu, J.Y. Yeh, Y.S. Chao, J.T. Hsu, H.P. Hsieh, and J.T. Horng Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity J. Biomed. Sci. 17 2010 13
10. E. Strocchi, F. Fornari, M. Minguzzi, L. Gramantieri, M. Milazzo, V. Rebuttini, S. Breviglieri, C.M. Camaggi, E. Locatelli, L. Bolondi, and M. Comes-Franchini Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma Eur. J. Med. Chem. 48 2012 391 401
11. P. Puthiyapurayil, B. Poojary, C. Chikkanna, and S.K. Buridipad Design, synthesis and biological evaluation of a novel series of 1,3,4-oxadiazole bearing N-methyl-4-(trifluoromethyl)phenyl pyrazole moiety as cytotoxic agents Eur. J. Med. Chem. 53 2012 203 210
12. I. Vujasinović, A. Paravić-Radičević, K. Mlinarić-Majerski, K. Brajša, and B. Bertoša Synthesis and biological validation of novel pyrazole derivatives with anticancer activity guided by 3D-QSAR analysis Bioorg. Med. Chem. 20 2012 2101 2110
13. S. David, R.S. Perkins, F.R. Fronczek, S. Kasiri, S.S. Mandal, and R.S. Srivastava Synthesis, characterization, and anticancer activity of ruthenium-pyrazole complexes J. Inorg. Biochem. 111 2012 33 39
14. S.L. Shen, J. Zhu, M. Li, B.X. Zhao, and J.Y. Miao Synthesis of ferrocenyl pyrazole-containing chiral aminoethanol derivatives and their inhibition against A549 and H322 lung cancer cells Eur. J. Med. Chem. 54 2012 287 294
15. J. Quirante, D. Ruiz, A. Gonzalez, C. López, M. Cascante, R. Cortés, R. Messeguer, C. Calvis, L. Baldomà, A. Pascual, Y. Guérardel, B. Pradines, M. Font-Bardía, T. Calvet, and C. Biot Platinum(II) and palladium(II) complexes with (N, N′) and (C, N, N′)-ligands derived from pyrazole as anticancer and antimalarial agents: synthesis, characterization and in vitro activities J. Inorg. Biochem. 105 2011 1720 1728
16. J.E. Westhead, and H.D. Price Quantitative assay of pyrazofurin, a new antiviral, antitumor antibiotic Antimicrob. Agents Chemother. 5 1 1974 90 91
17. O. Monasson, M. Ginisty, G. Bertho, C. Gravier-Pelletier, and Y.L. Merrer Efficient synthesis of polyfunctionalised enantiopure diazepanone scaffolds Tetrahedron Lett. 48 2007 8149 8152
18. M. Igarashi, N. Nakagawa, N. Doi, S. Hattori, H. Naganawa, and M. Hamada Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp. J. Antibiot. (Tokyo) 56 2003 580 583
19. M. Igarashi, Y. Takahashi, T. Shitara, H. Nakamura, H. Naganawa, T. Miyake, and Y. Akamatsu Caprazamycins, novel lipo-nucleoside antibiotics, from Streptomyces sp. J. Antibiot. (Tokyo) 58 2005 327 337
20. F. Sarabia, C. Vivar-García, C. García-Ruiz, L. Martín-Ortiz, and A. Romero-Carrasco Exploring the chemistry of epoxy amides for the synthesis of the 2″-epi-diazepanone core of liposidomycins and caprazamycins J. Org. Chem. 77 2012 1328 1339
21. S. Hirano, S. Ichikawa, and A. Matsuda Structure-activity relationship of truncated analogs of caprazamycins as potential anti-tuberculosis agents Bioorg. Med. Chem. 16 2008 5123 5133
22. B. Rosenberg, L. VanCamp, J.E. Trosko, and V.H. Mansour Platinum compounds: a new class of potent antitumour agents Nature 222 1969 385 386
23. P.J. Dysona, and G. Sava Metal-based antitumour drugs in the post genomic era Dalton Trans. 16 2006 1929 1933
24. G. Gasser, I. Ott, and N. Metzler-Nolte Organometallic anticancer compounds J. Med. Chem. 54 2011 3 25
25. C. Wetzel, P.C. Kunz, M.U. Kassack, A. Hamacher, P. Böhler, W. Watjen, I. Ott, R. Rubbiani, and B. Spingler Gold(I) complexes of water-soluble diphos-type ligands: synthesis, anticancer activity, apoptosis and thioredoxin reductase inhibition Dalton Trans. 40 2011 9212 9220
26. S.D. Köster, H. Alborzinia, S. Can, I. Kitanovic, S. Wölfl, R. Rubbiani, I. Ott, P. Riesterer, A. Prokop, K. Merza, and N. Metzler-Nolte A spontaneous gold(I)-azide alkyne cycloaddition reaction yields gold-peptide bioconjugates which overcome cisplatin resistance in a p53-mutant cancer cell line Chem. Sci. 3 2012 2062 2072
27. Y. Geldmacher, K. Splith, I. Kitanovic, H. Alborzinia, S. Can, R. Rubbiani, M.A. Nazif, P. Wefelmeier, A. Prokop, I. Ott, S. Wölfl, I. Neundorf, and W.S. Sheldrick Cellular impact and selectivity of half-sandwich organorhodium(III) anticancer complexes and their organoiridium(III) and trichloridorhodium(III) counterparts J. Biol. Inorg. Chem. 17 2012 631 646
28. F. Pelletier, V. Comte, A. Massard, M. Wenzel, S. Toulot, P. Richard, M. Picquet, P.L. Gendre, O. Zava, F. Edafe, A. Casini, and P.J. Dyson Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties J. Med. Chem. 53 2010 6923 6933
29. M. Hanif, A.A. Nazarov, A. Legin, M. Groessl, V.B. Arion, M.A. Jakupec, Y.O. Tsybin, P.J. Dyson, B.K. Kepplera, and C.G. Hartinger Maleimide- functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules Chem. Commun. 48 2012 1475 1477
30. H. Amouri, J. Moussa, A.K. Renfrew, P.J. Dyson, M.N. Rager, and L.-M. Chamoreau Discovery, structure, and anticancer activity of an iridium complex of diselenobenzoquinone Angew. Chem. Int. Ed. 49 2010 7530 7533
31. D. Pérez-Quintanilla, S. Gómez-Ruiz, Ž. Žižak, I. Sierra, S. Prashar, I. del Hierro, M. Fajardo, Z.D. Juranić, and G.N. Kaluderović A new generation of anticancer drugs: mesoporous materials modified with titanocene complexes Chem. Eur. J. 15 2009 5588 5597
32. A. Tzubery, and E.Y. Tshuva Cytotoxicity and hydrolysis of trans-Ti(IV) complexes of salen ligands: structure-activity relationship studies Inorg. Chem. 51 2012 1796 1804
33. S.H. van Rijt, H. Kostrhunova, V. Brabec, and P.J. Sadler Functionalization of osmium arene anticancer complexes with (poly)arginine: effect on cellular uptake, internalization, and cytotoxicity Bioconjug. Chem. 22 2011 218 226
34. Y.L.K. Tan, P. Pigeon, S. Top, E. Labbé, O. Buriez, E.A. Hillard, A. Vessières, C. Amatore, W.K. Leong, and G. Jaouen Ferrocenyl catechols: synthesis, oxidation chemistry and anti-proliferative effects on MDA-MB-231 breast cancer cells Dalton Trans. 41 2012 7537 7549
35. J. Quirante, F. Dubar, A. González, C. Lopez, M. Cascante, R. Cortés, I. Forfar, B. Pradines, and C. Biot Ferrocene-indole hybrids for cancer and malaria therapy J. Organomet. Chem. 696 2011 1011 1017
36. T.J. Kealy, and P.L. Pauson A new type of organo-iron compound Nature 168 1951 1039 1040
37. D. Plazuk, S. Top, A. Vessières, M.-A. Plamont, M. Huché, J. Zakrzewski, A. Makal, K. Woźniak, and G. Jaouen Organometallic cyclic polyphenols derived from 1,2-(α-keto tri or tetra methylene) ferrocene show strong antiproliferative activity on hormone-independent breast cancer cells Dalton Trans. 39 2010 7444 7450
38. D. Dive, and C. Biot Ferrocene conjugates of chloroquine and other antimalarials: the development of ferroquine, a new antimalarial ChemMedChem 3 2008 383 391
39. A. Mahajan, L. Kremer, S. Louw, Y. Guéradel, K. Chibale, and C. Biot Synthesis and in vitro antitubercular activity of ferrocene-based hydrazones Bioorg. Med. Chem. Lett. 21 2011 2866 2868
40. R.D. Miao, J. Wei, M.H. Lv, Y. Cai, Y.P. Du, X.P. Hui, and Q. Wang Conjugation of substituted ferrocenyl to thiadiazine as apoptosis-inducing agents targeting the Bax/Bcl-2 pathway Eur. J. Med. Chem. 46 2011 5000 5009
41. A.C. de Oliveira, E.A. Hillard, P. Pigeon, D.D. Rocha, F.A. Rodrigues, R.C. Montenegro, L.V. Costa-Lotufo, M.O. Goulart, and G. Jaouen Biological evaluation of twenty-eight ferrocenyl tetrasubstituted olefins: cancer cell growth inhibition, ROS production and hemolytic activity Eur. J. Med. Chem. 46 2011 3778 3787
42. P.Z. Li, and Z.Q. Liu Ferrocenyl-substituted curcumin: can it influence antioxidant ability to protect DNA? Eur. J. Med. Chem. 46 2011 1821 1826
43. G.M. Maguene, J. Jakhlal, M. Ladyman, A. Vallin, D.A. Ralambomanana, T. Bousquet, J. Maugein, J. Lebibi, and L. Pélinski Synthesis and antimycobacterial activity of a series of ferrocenyl derivatives Eur. J. Med. Chem. 46 2011 31 38
44. F. Wei, B.X. Zhao, B. Huang, L. Zhang, C.H. Sun, W.L. Dong, D.S. Shinc, and J.Y. Miao Design, synthesis, and preliminary biological evaluation of novel ethyl 1-(2′-hydroxy-3′-aroxypropyl)-3-aryl-1H-pyrazole-5-carboxylate Bioorg. Med. Chem. Lett. 16 2006 6342 6347
45. Y. Xia, Z.W. Dong, B.X. Zhao, X. Ge, N. Meng, D.S. Shin, and J.Y. Miao Synthesis and structure-activity relationships of novel 1-arylmethyl-3-aryl-1H- pyrazole-5-carbohydrazide derivatives as potential agents against A549 lung cancer cells Bioorg. Med. Chem. 15 2007 6893 6899
46. Y.S. Xie, X.H. Pan, B.X. Zhao, J.T. Liu, D.S. Shin, J.H. Zhang, L.W. Zheng, J. Zhao, and J.Y. Miao Synthesis, structure characterization and preliminary biological evaluation of novel 5-alkyl-2-ferrocenyl-6,7- dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives J. Organomet. Chem. 693 2008 1367 1374
47. X.H. Pan, X. Liu, B.X. Zhao, Y.S. Xie, D.S. Shin, S.L. Zhang, J. Zhao, and J.Y. Miao 5-Alkyl-2-ferrocenyl-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives inhibit growth of lung cancer A549 cell by inducing apoptosis Bioorg. Med. Chem. 16 2008 9093 9100
48. C.D. Fan, B.X. Zhao, F. Wei, G.H. Zhang, W.L. Dong, and J.Y. Miao Synthesis and discovery of autophagy inducers for A549 and H460 lung cancer cells, novel 1-(2′-hydroxy-3′-aroxypropyl)-3-aryl-1H-pyrazole-5- carbohydrazide derivatives Bioorg. Med. Chem. Lett. 18 2008 3860 3864
49. B.X. Zhao, L. Zhang, X.S. Zhu, M.S. Wan, J. Zhao, Y. Zhang, S.L. Zhang, and J.Y. Miao Synthesis and discovery of a novel pyrazole derivative as an inhibitor of apoptosis through modulating integrin β4, ROS, and p53 levels in vascular endothelial cells Bioorg. Med. Chem. 16 2008 5171 5180
50. J.H. Zhang, C.D. Fan, B.X. Zhao, D.S. Shin, W.L. Dong, Y.S. Xie, and J.Y. Miao Synthesis and preliminary biological evaluation of novel pyrazolo[1,5-a] pyrazin-4(5H)-one derivatives as potential agents against A549 lung cancer cells Bioorg. Med. Chem. 16 2008 10165 10171
51. Y. Xia, C.D. Fan, B.X. Zhao, J. Zhao, D.S. Shin, and J.Y. Miao Synthesis and structure-activity relationships of novel 1-arylmethyl-3-aryl-1H-pyrazole-5- carbohydrazide hydrazone derivatives as potential agents against A549 lung cancer cells Eur. J. Med. Chem. 43 2008 2347 2353
52. L.W. Zheng, L.L. Wu, B.X. Zhao, W.L. Dong, and J.Y. Miao Synthesis of novel substituted pyrazole-5-carbohydrazide hydrazone derivatives and discovery of a potent apoptosis inducer in A549 lung cancer cells Bioorg. Med. Chem. 17 2009 1957 1962
53. S. Lian, H. Su, B.X. Zhao, W.Y. Liu, L.W. Zheng, and J.Y. Miao Synthesis and discovery of pyrazole-5-carbohydrazide N-glycosides as inducer of autophagy in A549 lung cancer cells Bioorg. Med. Chem. 17 2009 7085 7092
54. X.L. Ding, H.Y. Zhang, L. Qi, B.X. Zhao, S. Lian, H.S. Lv, and J.Y. Miao Synthesis of novel pyrazole carboxamide derivatives and discovery of modulators for apoptosis or autophagy in A549 lung cancer cells Bioorg. Med. Chem. Lett. 19 2009 5325 5328
55. L.W. Zheng, J.H. Shao, B.X. Zhao, and J.Y. Miao Synthesis of novel pyrazolo[1,5-a]pyrazin-4(5H)-one derivatives and their inhibition against growth of A549 and H322 lung cancer cells Bioorg. Med. Chem. Lett. 21 2011 3909 3913
56. L.W. Zheng, J. Zhu, B.X. Zhao, Y.H. Huang, J. Ding, and J.Y. Miao Synthesis, crystal structure and biological evaluation of novel 2-(5-(hydroxymethyl)-3-phenyl-1H-pyrazol-1-yl)-1-phenylethanol derivatives Eur. J. Med. Chem. 45 2010 5792 5799
57. H.S. Lv, X.Q. Kong, Q.Q. Ming, X. Jin, J.Y. Miao, and B.X. Zhao Synthesis of 5-benzyl-2-phenylpyrazolo[1,5-a]pyrazin-4,6(5H,7H)-dione derivatives and discovery of an apoptosis inducer for H322 lung cancer cells Bioorg. Med. Chem. Lett. 22 2012 844 849
58. Y.S. Xie, H.L. Zhao, H. Su, B.X. Zhao, J.T. Liu, J.K. Li, H.S. Lv, B.S. Wang, D.S. Shin, and J.Y. Miao Synthesis, single-crystal characterization and preliminary biological evaluation of novel ferrocenyl pyrazolo[1,5-a]pyrazin- 4(5H)-one derivatives Eur. J. Med. Chem. 45 2010 210 218
59. P. Seiler, and J.D. Dunitz The structure of triclinic ferrocene at 101, 123 and 148 K Acta Crystallogr. B 35 1979 2020 2032
60. G. Tabbì, C. Cassino, G. Cavigiolio, D. Colangelo, A. Ghiglia, I. Viano, and D. Osella Water stability and cytotoxic activity relationship of a series of ferrocenium derivatives. ESR insights on the radical production during the degradation process J. Med. Chem. 45 2002 5786 5796
61. A. Vessières, S. Top, W. Beck, E. Hillard, and G. Jaouen Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects Dalton Trans. 4 2006 529 541
62. I. Damljanović, M. Čolović, M. Vukić ević, D. Manojlović, N. Radulović, K. Wurst, G. Laus, Z. Ratković, M. Joksović, and R.D. Vukićević Synthesis, spectral characterization and electrochemical properties of 1H-3-(o-, m- and p-ferrocenylphenyl)-1-phenylpyrazole-4-carboxaldehydes J. Organomet. Chem. 694 2009 1575 1580
63. J. Skiba, A. Rajnisz, K.N. de Oliveira, I. Ott, J. Solecka, and K. Kowalski Ferrocenyl bioconjugates of ampicillin and 6-aminopenicillinic acid-synthesis, electrochemistry and biological activity Eur. J. Med. Chem. 57 2012 234 239
64. Z.A. Stewart, M.D. Westfall, and J.A. Pietenpol Cell-cycle dysregulation and anticancer therapy Trends Pharmacol. Sci. 24 2003 139 145
65. G.M. Sheldrick A short history of SHELX Acta. Crystallogr. A. Found. Crystallogr. 64 2008 112 122